

PATENT Attorney Reference Number 899-73077-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nelson et al.

Application No. 10/564,369

Filed: January 11, 2006

Confirmation No. Not yet assigned.

METHODS OF TREATMENT AND

DIAGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE

SEQUENCES

Examiner: Not yet assigned.

Art Unit: Not yet assigned.

Attorney Reference No. 899-73077-04

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the

date shown below.

Attorney or Agent for Applicant(

Date Mailed May 12, 2006

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- 冈 Information Disclosure Statement Form 1449 and five references cited thereon
- \boxtimes The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- \boxtimes Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLF

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

cc:

Docketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nelson et al.

Application No. 10/564,369 **Filed:** January 11, 2006

Confirmation No. Not yet assigned.

For: METHODS OF TREATMENT AND

DIAGNOSIS USING MODULATORS OF VIRUS-INDUCED CELLULAR GENE

SEQUENCES

Examiner: Not yet assigned. Art Unit: Not yet assigned.

Attorney Reference No. 899-73077-04

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

nte Mailed <u>May 12, 2006</u>

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are five English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, Deposit Authority is given on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMA

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

Cite No.

(optional)

Examiner's

Initials*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-73077-04
Application Number	10/564,369
Filing Date	January 11, 2006
First Named Inventor	Nelson
Art Unit	
Examiner Name	

Name of Applicant or Patentee

U.S. PATENT DOCUMENTS

Number

opies of U.S. atent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Publication Date

		FO	REIGN PATENT	DOCUMENTS		
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
		Guan et al., "Design and synthesis of aminopropyl tetrahydoindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase," Bioorganic & Medicinal Chemistry Letters 14:187-190 (2004) Macdonald et al., "The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity," J. General Virology 85:721-729 (2004) Missbach et al., "A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo," Bone 24(5):437-449 (1999) Moasser et al., "Inhibition of Src Kinases by a Selective Tyrosine Kinase Inhibitor Causes Mitotic Arrest," Cancer Research 59:6145-6152 (1999) Schang, "Effects of pharmacological cyclin-dependent kinase inhibitors on viral				

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

transcription and replication," Biochimica et Biophysica Acta 1697:197-209 (2004)

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.